Finance entity
Every one of those 1 sits in a single category, markets. FDA is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 2.6 for the same window.
Last mentioned: Mar 25, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, markets. FDA is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 2.6 for the same window. Their average consequence score of 5 runs below the beat's 6.3 for that window. We currently track 1 Finance story that mention Sarepta Therapeutics, all published on March 25, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 84 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Sarepta Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Clinical Data Release
Early data for FSHD and DM1 therapies reported by STAT and Endpoints News.
Options Surge
Traders purchase large volumes of call options following the clinical updates.
Price Target Update
Brokerages adjust targets, including a raise to $9.00 by some analysts.
Financial Results
Sarepta files results of operations and financial condition with the SEC.
Traders have flooded Sarepta Therapeutics with call options following positive early-stage data for its RNA-based rare disease therapies. This surge in bullish sentiment suggests high market confidence in the company's clinical pipeline expansion beyond its core Duchenne muscular dystrophy franchise.
Sarepta Therapeutics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
